Point-of-care HIV viral load and targeted drug resistance mutation testing versus standard care for Kenyan children on antiretroviral therapy (Opt4Kids): an open-label, randomised controlled trial

被引:14
作者
Patel, Rena C. [1 ,2 ,13 ]
Oyaro, Patrick [4 ]
Thomas, Katherine K. [2 ]
Wagude, James [5 ]
Mukui, Irene [6 ]
Brown, Evelyn [7 ]
Hassan, Shukri A. [1 ]
Kinywa, Eunice [8 ]
Oluoch, Frederick [8 ]
Odhiambo, Francesca [9 ]
Oyaro, Boaz [10 ]
Kingwara, Leonard [11 ]
Karauki, Enericah [7 ]
Yongo, Nashon [7 ]
Otieno, Lindah [9 ]
John-Stewart, Grace C. [1 ,2 ,3 ]
Abuogi, Lisa L. [12 ]
机构
[1] Univ Washington, Dept Med, Seattle, WA USA
[2] Univ Washington, Dept Global Hlth, Seattle, WA USA
[3] Univ Washington, Dept Pediat & Epidemiol, Seattle, WA USA
[4] Hlth Innovat Kenya HIK, Kisuma, Kenya
[5] Dept Hlth, Siaya Cty, Kenya
[6] Drugs Neglected Dis Initiat DNDI, Nairobi, Kenya
[7] UWKenya, Nairobi, Kenya
[8] Dept Hlth, Kisumu Cty, Kenya
[9] Kenya Govt Med Res Ctr, Family AIDS Care & Educ Serv, Kisumu, Kenya
[10] Kenya Med Res Inst CDC, Kisian, Kenya
[11] Kenya Minist Hlth, Natl HIV Reference Lab, Nairobi, Kenya
[12] Univ Colorado, Dept Pediat, Denver, CO USA
[13] Univ Washington, Dept Med, Seattle, WA 98104 USA
关键词
TREATMENT OUTCOMES; SCALE-UP; AFRICAN; COUNTRIES; INFANTS;
D O I
10.1016/S2352-4642(22)00191-2
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Feasible, scalable, and cost-effective approaches to ensure virological suppression among children living with HIV are urgently needed. The aim of the Opt4Kids study was to determine the effect of point of care viral load and targeted drug resistance mutation testing in improving virological suppression among children on antiretroviral therapy (ART) in Kenya. Methods In this open-label, individually randomised controlled trial, we enrolled children living with HIV aged 1-14 years and who were either newly initiating or already receiving ART at five study facilities in Kenya. Participants were randomly allocated 1:1 to receive the intervention of point-of-care viral load testing every 3 months, targeted drug resistance mutation testing, and clinical decision support (point-of-care testing) or to receive the standard care (control group), stratified by facility site and age groups (1-9 years vs 10-14 years). Investigators were masked to the randomised group. The primary efficacy outcome was virological suppression (defined as a viral load of <1000 copies per mL) by point-of-care viral load testing at 12 months after enrolment in all participants with an assessment. This study is registered with ClinicalTrials.gov, NCT03820323. Findings Between March 7, 2019, and December 31, 2020, we enrolled 704 participants. Median age at enrolment was 9 years (IQR 7-12), 344 (49%) participants were female and 360 (51%) were male, and median time on ART was 5.8 years (IQR 3.1-8.6). 536 (76%) of 704 had documented virological suppression at enrolment. At 12 months after enrolment, the proportion of participants achieving virological suppression in the intervention group (283 [90%] of 313 participants with a 12 month point-of-care viral load test) did not differ from that in the control group (289 [92%] of 315; risk ratio [RR] 0.99, 95% CI 0.94-1.03; p=0.55). We identified 138 episodes of viraemia in intervention participants, of which 107 (89%) samples successfully underwent drug resistance mutation testing and 91 (85%) had major drug resistance mutations. The median turnaround time for viral load results was 1 day (IQR 0-1) in the intervention group and 15 days (10-21) in the control group. Interpretation Point-of-care viral load testing decreased turnaround time and targeted drug resistance mutation testing identified a high prevalence of HIV drug resistance mutations in children living with HIV, but the combined approach did not increase rates of virological suppression. Further research in combination interventions, including point-of-care viral load and drug resistance mutation testing coupled with psychosocial support, is needed to optimise virological suppression for children living with HIV. Copyright (C) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码:681 / 691
页数:11
相关论文
共 28 条
[1]   Suboptimal Viral Suppression Rates Among HIV-Infected Children in Low- and Middle-Income Countries: A Meta-analysis [J].
Boerma, Ragna S. ;
Boender, T. Sonia ;
Bussink, Anton P. ;
Calis, Job C. J. ;
Bertagnolio, Silvia ;
de Wit, Tobias F. Rinke ;
van Hensbroek, Michael Boele ;
Sigaloff, Kim C. E. .
CLINICAL INFECTIOUS DISEASES, 2016, 63 (12) :1645-1654
[2]   Costs of Point-of-Care Viral Load Testing for Adults and Children Living with HIV in Kenya [J].
Bulterys, Michelle Ann ;
Oyaro, Patrick ;
Brown, Evelyn ;
Yongo, Nashon ;
Karauki, Enericah ;
Wagude, James ;
Kingwara, Leonard ;
Bowen, Nancy ;
Njogo, Susan ;
Wagner, Anjuli D. ;
Mukui, Irene ;
Oluoch, Frederick ;
Abuogi, Lisa ;
Patel, Rena ;
Sharma, Monisha .
DIAGNOSTICS, 2021, 11 (01)
[3]   Performance and usability of Cepheid GeneXpert HIV-1 qualitative and quantitative assay in Kenya [J].
Bwana, Priska ;
Ageng'o, Joshua ;
Mwau, Matilu .
PLOS ONE, 2019, 14 (03)
[4]   Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial [J].
Drain, Paul K. ;
Dorward, Jienchi ;
Violette, Lauren R. ;
Quame-Amaglo, Justice ;
Thomas, Katherine K. ;
Samsunder, Natasha ;
Ngobese, Hope ;
Mlisana, Koleka ;
Moodley, Pravikrishnen ;
Donnell, Deborah ;
Barnabas, Ruanne V. ;
Naidoo, Kogieleum ;
Karim, Salim S. Abdool ;
Celum, Connie ;
Garrett, Nigel .
LANCET HIV, 2020, 7 (04) :E229-E237
[5]   Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland [J].
Etoori, David ;
Ciglenecki, Iza ;
Ndlangamandla, Mpumelelo ;
Edwards, Celeste G. ;
Jobanputra, Kiran ;
Pasipamire, Munyaradzi ;
Maphalala, Gugu ;
Yang, Chunfu ;
Zabsonre, Inoussa ;
Kabore, Serge M. ;
Goiri, Javier ;
Teck, Roger ;
Kerschberger, Bernhard .
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 (10)
[6]   The viral load monitoring cascade in a resource-limited setting: A prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho [J].
Glass, Tracy Renee ;
Motaboli, Lipontso ;
Nsakala, Bienvenu ;
Lerotholi, Malebanye ;
Vanobberghen, Fiona ;
Amstutz, Alain ;
Lejone, Thabo Ishmael ;
Muhairwe, Josephine ;
Klimkait, Thomas ;
Labhardt, Niklaus Daniel .
PLOS ONE, 2019, 14 (08)
[7]   Factors associated with self-reported adherence among adolescents on antiretroviral therapy in Zimbabwe [J].
Gross, Robert ;
Bandason, Tsitsi ;
Langhaug, Lisa ;
Mujuru, Hilda ;
Lowenthal, Elizabeth ;
Ferrand, Rashida .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2015, 27 (03) :322-326
[8]   Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study [J].
Hermans, Lucas E. ;
Moorhouse, Michelle ;
Carmona, Sergio ;
Grobbee, Diederick E. ;
Hofstra, L. Marije ;
Richman, Douglas D. ;
Tempelman, Hugo A. ;
Venter, Willem D. F. ;
Wensing, Annemarie M. J. .
LANCET INFECTIOUS DISEASES, 2018, 18 (02) :188-197
[9]   High prevalence of virological failure and HIV drug mutations in a first-line cohort of Malawian children [J].
Huibers, M. H. W. ;
Moons, P. ;
Cornelissen, M. ;
Zorgdrager, F. ;
Maseko, N. ;
Gushu, M. B. ;
Iwajomo, O. H. ;
van Hensbroek, M. Boele ;
Calis, J. C. J. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (12) :3471-3475
[10]   Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13 [J].
Hunt, Gillian M. ;
Ledwaba, Johanna ;
Salimo, Anna ;
Kalimashe, Monalisa ;
Thu-Ha Dinh ;
Jackson, Debra ;
Sherman, Gayle ;
Puren, Adrian ;
Ngandu, Nobubelo K. ;
Lombard, Carl ;
Morris, Lynn ;
Goga, Ameena .
BMC INFECTIOUS DISEASES, 2019, 19 (Suppl 1) :787